The Medical Advisor

Cancer treatment has transformed dramatically over the past decade. From chemotherapy and radiation to targeted therapies, each advance has sought to tip the balance in favor of the patient. Now, cell-based immunotherapies — therapies that harness and engineer the body’s immune system to fight cancer — are taking center stage. Two of the most promising approaches are CAR-T and CAR-NK cell therapies. But what makes them different, and how are emerging innovations, including AI and NK cell expansion, shaping the future of immunotherapy? Understanding CAR-T Therapy CAR-T (Chimeric Antigen Receptor T-cell) therapy involves harvesting a patient’s T cells, genetically engineering them to recognize specific cancer antigens, and reinfusing them into the body. These modified T cells can detect and destroy cancer cells with remarkable precision. Strengths of CAR-T: High efficacy in blood cancers: Durable remissions have been reported in leukemia and lymphoma patients. Long-term immune memory: ...

NAC vs NAD vs NR vs NMN ? Due to the small alphabetical differences, these supplements are often mixed up and confused by most consumers. We will cover the essentials and explain about each of these supplements below. NAD NAD is derived from Nicotinamide Riboside (NR). The levels of NAD in our body determine the speed of aging process. In younger cells and tissues, the levels of NAD are higher. As a result, younger people tend to have better physical activity, cognitive function and potential for cell repair and regeneration. As we grow, the levels of NAD in our body start to decline. This is reflected in the form of slowed cognitive response, loss of memory and reduced agility. Related:  Longevity and Anti Aging 101: What You Need to Know  (A Comprehensive Guide) Research suggests it may be possible to reverse mitochondrial decay with dietary supplements that increase cellular levels of a molecule called NAD (nicotinamide adenine dinuc...

You’ve likely seen the claims: “Sugar feeds cancer — eliminate carbs.” “Keto starves tumors.” “Plant-based diets reverse cancer.” “Fasting kills cancer cells.” These ideas sound intuitive. Some are supported by laboratory or animal studies. Yet when tested rigorously in humans, most anti-cancer diet claims fail to show meaningful clinical benefit . This article explains why, what diet can realistically do for cancer risk and outcomes, and how nutrition fits into a modern, evidence-informed cancer strategy. 1. Lab Success Doesn’t Translate to Human Reality Many diet-based cancer claims originate from: Cell culture experiments Mouse models Short-term metabolic interventions In these controlled environments, researchers can deprive cancer cells of glucose or nutrients abruptly. Humans, however, are complex systems with: Multiple organs and hormones Immune responses Gut microbiomes Tumors that evolve and adapt What slows cancer growth in a dish often has minimal impact in real patients. R...

Background on Salivary Gland Cancer Salivary gland cancer is a rare malignancy affecting the salivary glands (e.g., parotid, submandibular, or sublingual glands), with subtypes like adenoid cystic carcinoma and mucoepidermoid carcinoma. Standard treatments include surgery, radiation, and sometimes chemotherapy, but outcomes vary depending on stage and subtype, with advanced cases often having limited options. ​ Exploring alternative and adjunctive therapies for stage 4 salivary gland cancer is understandable, especially when conventional treatments have limited efficacy.  There is limited publicly available, peer-reviewed evidence specifically documenting success stories of Fenbendazole, Ivermectin, Mebendazole, Vitamin D3, Curcumin, Berberine and Cimetidine use in treating salivary gland cancer in humans.  Ivermectin and Fenbendazole, traditionally used as antiparasitics (Fenbendazole in veterinary medicine and Ivermectin in humans and animals), have gained attention for thei...

Abstract In 2022, approximately 20 million new cancer cases and 9.7 million cancer deaths occurred worldwide. By 2050, new cases are projected to double, driven by population growth, aging, and increased exposure to risk factors. Up to 40% of cancers may be preventable by addressing lifestyle and environmental risk factors. Numerous nutraceuticals and repurposed drugs exhibit chemoprophylactic properties. Epigallocatechin gallate (EGCG), a polyphenol in green tea, appears to be the most effective agent against multiple cancers, followed by curcumin, a . polyphenol derived from turmeric (Curcuma longa), vitamin D, and omega-3 fatty acids. Using artificial intelligence and leveraging synergistic effects among these compounds, we developed the ROOT 3, ROOT 4, ROOT 5, ROOT 6, and ROOT 9 chemoprophylactic protocols. The mechanistic activity of each nutraceutical is described, along with the estimated risk reduction for the most common types of cancer. These protocols may offer a low-risk an...

Insights from Dr. Paul Marik and Dr. Justus Hope on the hidden drivers of cancer relapse, featuring the revamped CSC Cancer Tree and practical strategies using repurposed drugs and natural compounds. Cancer treatment often succeeds—until it doesn’t. A tumor shrinks. A scan looks clean. The patient goes home hopeful. And then… the cancer returns, sometimes more aggressive than before. The answer lies with a small population of cells that most standard treatments ignore: cancer stem cells (CSCs). These cells not only survive chemotherapy and radiation but adapt and return, driving relapse, metastasis, and mortality.   Dr. Paul Marik and Dr. Justus Hope have collaborated to highlight this critical issue, offering a free guide that explains CSCs, why conventional therapies fail against them, and how safe, affordable repurposed drugs and natural compounds can target them for long-term remission. This guide builds on earlier work, including the CSC Cancer Tree from Dr. Hope's 2020 book,...